Organization
Zealand Pharma
13 clinical trials
Clinical trial
A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital HyperinsulinismStatus: Completed, Estimated PCD: 2020-08-31
Clinical trial
A Randomised, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570 Administered in Subjects With Overweight or ObesityStatus: Recruiting, Estimated PCD: 2024-11-15
Clinical trial
A Randomized, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy SubjectsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital HyperinsulinismStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 3, Single-administration, Open-label Trial to Assess the Efficacy, Safety, PK, and PD of Dasiglucagon When Administered as a Rescue Therapy for Severe Hypoglycemia in Pediatric Patients Below 6 Years of Age With Type 1 DiabetesStatus: Recruiting, Estimated PCD: 2024-03-25
Clinical trial
A Double-Blind, Placebo-Controlled, Cross-over Trial, Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated AdultsStatus: Withdrawn, Estimated PCD: 2023-02-01
Clinical trial
A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome (SBS)Status: Completed, Estimated PCD: 2023-02-02
Clinical trial
A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital HyperinsulinismStatus: Completed, Estimated PCD: 2022-03-07
Clinical trial
A Phase 3b, Randomized, Double-blind, Crossover Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With Type 1 Diabetes MellitusStatus: Completed, Estimated PCD: 2019-07-30
Clinical trial
A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Glepaglutide in Patients With Short Bowel Syndrome (SBS)Status: Completed, Estimated PCD: 2022-07-26
Clinical trial
A First-in-human, Randomised, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy SubjectsStatus: Completed, Estimated PCD: 2023-01-12
Clinical trial
A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 TrialStatus: , Estimated PCD: 2025-04-01
Clinical trial
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)Status: Recruiting, Estimated PCD: 2024-12-31